Table 4: Changes between baseline and response scans and factors predictive of benefit from gemcitabine-based chemotherapy

A:  Overall changes in uptake in tumour lesions after therapy

 

All lesions (n=16)

Primary tumour (n=10)

Liver metastases (n=6)

Percentage change in SUVmax after therapy. Mean (SD)

3.0 (21)

1.6 (26)

5.4 (13)

Percentage change in SUVmean after therapy. Mean (SD)

-6.4 (14)

-8.1 (15)

-3.7 (14)

 

 

 

 

B: Changes in tumour uptake in patients with and without clinical benefit from gemcitabine chemotherapy

 
 

 Patients with Clinical benefit

(n=6)

Patients with no Clinical benefit

(n=4)

p-value

(t-test)

Mean (SD) percentage reduction in SUVmax after therapy.

2.7 (25.4)

3.3 (17.8)

0.27

Mean (SD) percentage reduction in SUVmean after therapy.

-10.5 (13.8)

- 2.4 (16.7)

0.78

 

C: Changes in uptake in tumour lesions with chemotherapy regimen

 

 
 

 Gemcitabine alone

(n=5)

Gemcitbine- all combintaion

(n=11)

Gemcitabine –Capecitabine (n=(n=5)

Gem+Nab-paclitaxel

(n=3)

Mean (SD) percentage reduction in SUVmax after therapy

16.7 (20.1) *

3.0 (21.2)*

-11.5 (13.7)

7.0 (15.1)

Mean (SD) percentage reduction in SUVmean after therapy

3.0 (9.1) *

- 6.4 (14.3)*

-16.1 (5.6)

-11.3 (18.4)

*Significant (p < 0.05) difference in FLT uptake was observed when gemcitabine was compared with gemcitabine-capecitabine but not with any of the other comparisons.